Skip to main content

Table 3 The change of volume, expenditures, and DDDc of policy-related antihypertensive drugs in the pre- and post-“4 + 7” periods

From: The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis

  Volume (thousand DDD) Expenditures (thousand CNY) DDDc (CNY)
  Pre- Post- GR (%) Pre- Post- GR (%) Pre- Post- GR (%)
“4 + 7” List drugs 24.53 47.13 92.15 73.81 37.44 -49.28 3.01 0.79 -73.60
Bid-winning drugs 3.02 41.35 1268.54 5.76 17.66 206.42 1.91 0.43 -77.61
Non-winning drugs 21.51 5.78 -73.11 68.05 19.78 -70.93 3.16 3.42 8.11
Alternative drugs 48.36 60.46 25.04 151.16 186.11 23.12 3.13 3.08 -1.53
Overall policy-related 72.89 107.60 47.63 224.97 223.55 -0.63 3.09 2.08 -32.69
  1. DDD, Daily Defined Dose; CNY, Chinese Yuan; DDDc, Defined Daily Drug cost; GR, Growth Rate. Pre- refers to March to December 2018; Post- refers to March to December 2019